The single dose poloxamer 407 model of hyperlipidemia; systemic effects on lipids assessed using pharmacokinetic methods, and its effects on adipokines

Journal of Pharmacy and Pharmaceutical Sciences

Volumn 16, Issue 1, 2013, Pages 65-73

  Chaudhary, Hetal R ^a   Brocks, Dion R ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Adiponectin; Interleukin 6; Leptin; Lipoproteins; Pharmacokinetics; Tumour necrosis factor

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 6; LEPTIN; LIPID; POLOXAMER; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CHOLESTEROL BLOOD LEVEL; HYPERLIPIDEMIA; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84873895092     PISSN: None     EISSN: 14821826     Source Type: Journal    
DOI: 10.18433/j37g7m     Document Type: Article

References (43)

1. Ackermann D, Jones J, Barona J, Calle MC, Kim JE, Lapia B, Volek JS, Mcintosh M, Kalynych C, Najm W, Lerman RH, Fernandez ML. Waist circumference is positively correlated with markers of inflammation and negatively with adiponectin in women with metabolic syndrome. Nutr Res 31: 197-204.
2. Bailer AJ. Testing for the equality of area under the curves when using destructive measurement techniques. J Pharmacokinet Biopharm 1988; 16: 303-309.
3. Blonder JM, Baird L, Fulfs JC, Rosenthal GJ. Dose-dependent hyperlipidemia in rabbits following administration of poloxamer 407 gel. Life Sci 1999; 65: PL261-266.
4. Brocks DR, Ala S, Aliabadi HM. The effect of increased lipoprotein levels on the pharmacokinetics of cyclosporine A in the laboratory rat. Biopharm Drug Dispos 2006; 27: 7-16.
5. Brocks DR, Hamdy DA, Ben-Eltriki M, Patel JP, Ao SE-K. Effect of rat serum lipoproteins on mRNA levels and amiodarone metabolism by cultured primary rat hepatocytes. J Pharm Sci 2013; 102: 262-270.
6. De Heredia FP, Gomez-Martinez S, Marcos A. Obesity, inflammation and the immune system. Proc Nutr Soc 2012; 71: 332-338.
7. Eliot LA, Foster RT, Jamali F. Effects of hyperlipidemia on the pharmacokinetics of nifedipine in the rat. Pharm Res 1999; 16: 309-313.
8. Fukushima K, Kobuchi S, Shibata M, Takada K, Sugioka N. Decrease in brain distribution of fluvoxamine in experimental hyperlipidemic rats. J Pharm Pharm Sci 14: 414-424.
9. Fukushima K, Kobuchi S, Shibata M, Takada K, Sugioka N. Decrease in brain distribution of fluvoxamine in experimental hyperlipidemic rats. J Pharm Pharm Sci 2011; 14: 414-424.
10. Gannage-Yared MH, Khalife S, Semaan M, Fares F, Jambart S, Halaby G. Serum adiponectin and leptin levels in relation to the metabolic syndrome, androgenic profile and somatotropic axis in healthy non-diabetic elderly men. Eur J Endocrinol 2006; 155: 167-176.
11. Gawronska-Szklarz B, Drozdzik M, Wojcicki J, Zakrzewski J. Effect of experimental hyperlipidemia on the pharmacokinetics of digoxin. Acta Pol Pharm 1994; 51: 271-274.
12. Guerre-Millo M. Adipose tissue and adipokines: for better or worse. Diabetes Metab 2004; 30: 13-19.
13. Guo F, Huang C, Liao X, Wang Y, He Y, Feng R, Li Y, Sun C. Beneficial effects of mangiferin on hyperlipidemia in high-fat-fed hamsters. Mol Nutr Food Res 55: 1809-1818.
14. Holt PR, Dominguez AA. Triton-induced hyperlipidemia: a model for studies of intestinal lipoprotein production. Am J Physiol 1980; 238: G453-457.
15. Johnston TP. The P-407-induced murine model of dose-controlled hyperlipidemia and atherosclerosis: a review of findings to date. J Cardiovasc Pharmacol 2004; 43: 595-606.
16. Johnston TP, Palmer WK. Mechanism of poloxamer 407-induced hypertriglyceridemia in the rat. Biochem Pharmacol 1993; 46: 1037-1042.
17. Joo IW, Ryu JH, Oh HJ. The influence of Sam-Chil-Geun (Panax notoginseng) on the serum lipid levels and inflammations of rats with hyperlipidemia induced by poloxamer-407. Yonsei Med J 51: 504-510.
18. Kacevska M, Robertson GR, Clarke SJ, Liddle C. Inflammation and CYP3A4-mediated drug metabolism in advanced cancer: impact and implications for chemotherapeutic drug dosing. Expert Opin Drug Metab Toxicol 2008; 4: 137-149.
19. Kim MS, Wang S, Shen Z, Kochansky CJ, Strauss JR, Franklin RB, Vincent SH. Differences in the pharmacokinetics of peroxisome proliferator-activated receptor agonists in genetically obese Zucker and sprague-dawley rats: implications of decreased glucuronidation in obese Zucker rats. Drug Metab Dispos 2004; 32: 909-914.
20. Kobuchi S, Fukushima K, Shibata M, Ito Y, Sugioka N, Takada K. Pharmacokinetics of clomipramine, an antidepressant, in poloxamer 407-induced hyperlipidaemic model rats. J Pharm Pharmacol 63: 515-523.
21. Lee JH, Oh JH, Lee YJ. Effects of experimental hyperlipidaemia on the pharmacokinetics of docetaxel in rats. Xenobiotica 41: 797-804.
22. Lee JH, Oh JH, Lee YJ. Effects of experimental hyperlipidemia on the pharmacokinetics of tadalafil in rats. J Pharm Pharm Sci 2012; 15: 528-537.
23. Lee YS, Kim YW, Kim SG, Lee I, Lee MG, Kang HE. Effects of poloxamer 407-induced hyperlipidemia on the pharmacokinetics of carbamazepine and its 10,11-epoxide metabolite in rats: Impact of decreased expression of both CYP3A1/2 and microsomal epoxide hydrolase. Eur Neuropsychopharmacol 22: 431-440.
24. Lee YS, Kim YW, Kim SG, Lee I, Lee MG, Kang HE. Effects of poloxamer 407-induced hyperlipidemia on the pharmacokinetics of carbamazepine and its 10,11-epoxide metabolite in rats: Impact of decreased expression of both CYP3A1/2 and microsomal epoxide hydrolase. Eur Neuropsychopharmacol 2012; 22: 431-440.
25. Lee YS, Yoon JN, Yoon IS, Lee MG, Kang HE. Pharmacokinetics of verapamil and its metabolite norverapamil in rats with hyperlipidaemia induced by poloxamer 407. Xenobiotica 2012.
26. Levine S, Saltzman A. A procedure for inducing sustained hyperlipemia in rats by administration of a surfactant. J Pharmacol Toxicol Methods 2007; 55: 224-226.
27. Li C, Palmer WK, Johnston TP. Disposition of poloxamer 407 in rats following a single intraperitoneal injection assessed using a simplified colorimetric assay. J Pharm Biomed Anal 1996; 14: 659-665.
28. Margoni A, Perrea DN, Vlachos I, Prokopaki G, Pantopoulou A, Fotis L, Kostaki M, Papavassiliou AG. Serum leptin, adiponectin and tumor necrosis factor-alpha in hyperlipidemic rats with/without concomitant diabetes mellitus. Mol Med 17: 36-40.
29. Matsubara M, Maruoka S, Katayose S. Decreased plasma adiponectin concentrations in women with dyslipidemia. J Clin Endocrinol Metab 2002; 87: 2764-2769.
30. Nieto-Vazquez I, Fernandez-Veledo S, Kramer DK, Vila-Bedmar R, Garcia-Guerra L, Lorenzo M. Insulin resistance associated to obesity: the link TNF-alpha. Arch Physiol Biochem 2008; 114: 183-194.
31. Nikkila EA, Ylikahri R, Huttunen JK. Gemfibrozil: effect on serum lipids, lipoproteins, postheparin plasma lipase activities and glucose tolerance in primary hypertriglyceridaemia. Proc R Soc Med 1976; 69 Suppl 2: 58-63.
32. Palmer WK, Emeson EE, Johnston TP. Poloxamer 407-induced atherogenesis in the C57BL/6 mouse. Atherosclerosis 1998; 136: 115-123.
33. Patel JP, Brocks DR. Effect of experimental hyperlipidaemia on the electrocardiographic effects of repeated doses of halofantrine in rats. Br J Pharmacol 161: 1427-1440.
34. Pec EA, Wout ZG, Johnston TP. Biological activity of urease formulated in poloxamer 407 after intraperitoneal injection in the rat. J Pharm Sci 1992; 81: 626-630.
35. Shayeganpour A, Jun AS, Brocks DR. Pharmacokinetics of Amiodarone in hyperlipidemic and simulated high fat-meal rat models. Biopharm Drug Dispos 2005; 26: 249-257.
36. Shayeganpour A, Korashy H, Patel JP, El-Kadi AO, Brocks DR. The impact of experimental hyperlipidemia on the distribution and metabolism of amiodarone in rat. Int J Pharm 2008; 361: 78-86.
37. Shayeganpour A, Lee SD, Wasan KM, Brocks DR. The influence of hyperlipoproteinemia on in vitro distribution of amiodarone and desethylamiodarone in human and rat plasma. Pharm Res 2007; 24: 672-678.
38. Shibata R, Ouchi N, Murohara T. Adiponectin and cardiovascular disease. Circ J 2009; 73: 608-614.
39. Sniderman AD, Blank D, Zakarian R, Bergeron J, Frohlich J. Triglycerides and small dense LDL: the twin Achilles heels of the Friedewald formula. Clin Biochem 2003; 36: 499-504.
40. Sullivan MP, Cerda JJ, Robbins FL, Burgin CW, Beatty RJ. The gerbil, hamster, and guinea pig as rodent models for hyperlipidemia. Lab Anim Sci 1993; 43: 575-578.
41. Van De Woestijne AP, Monajemi H, Kalkhoven E, Visseren FL. Adipose tissue dysfunction and hypertriglyceridemia: mechanisms and management. Obes Rev 12: 829-840.
42. Wout ZG, Pec EA, Maggiore JA, Williams RH, Palicharla P, Johnston TP. Poloxamer 407-mediated changes in plasma cholesterol and triglycerides following intraperitoneal injection to rats. J Parenter Sci Technol 1992; 46: 192-200.
43. Xu L, Liu Y, Wang T, Qi Y, Han X, Xu Y, Peng J, Tang X. Development and validation of a sensitive and rapid non-aqueous LC-ESI-MS/MS method for measurement of diosgenin in the plasma of normal and hyperlipidemic rats: a comparative study. J Chromatogr B Analyt Technol Biomed Life Sci 2009; 877: 1530-1536.